What is the 13F Pro Quality Score for NVCR?

13F Pro ranks NovoCure Ltd (NVCR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NVCR's current score at https://13fpro.ai/research/NVCR (free sign-up required for the full ranking).

Which hedge funds own the most NVCR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NVCR include FMR, BlackRock,, Soleus Capital Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NVCR as soon as new 13F filings post.

Where does 13F Pro source NVCR data?

All NovoCure Ltd fundamentals and ownership data come directly from SEC EDGAR. NovoCure Ltd files with the SEC under CIK 1645113. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NVCR in?

NovoCure Ltd (NVCR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NVCR research updated on 13F Pro?

NVCR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NovoCure Ltd(NVCR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1645113 NVCR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NVCR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NovoCure Ltd (NVCR), a Healthcare sector company. NVCR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), NovoCure Ltd reports quarterly revenue of $174.1M, net income of $-71.1M, free cash flow of $-18.7M. Top institutional holders of NVCR by reported 13-F value include FMR, BlackRock,, Soleus Capital Management, L.P., based on the most recent SEC filings. NVCR trades on the Nasdaq exchange and files with the SEC under CIK 1645113. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NovoCure Ltd directly from SEC EDGAR.

Revenue

Q1 2026

$174.1M

Net Income

Q1 2026

$-71.1M

Free Cash Flow

Q1 2026

$-18.7M

ROIC

Q1 2026

-20.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+12.5% YoY

$605.2MFY 2024

FY20 $494.4MFY21 $535.0MFY22 $537.8MFY24 $605.2M

Net Income

-82.2% YoY

$-168.6MFY 2024

FY20 $19.8MFY21 $-58.4MFY22 $-92.5MFY24 $-168.6M

Operating Income

-90.4% YoY

$-170.5MFY 2024

FY20 $30.4MFY21 $-44.3MFY22 $-89.5MFY24 $-170.5M

EPS (Diluted)

-77.3% YoY

$-1.56FY 2024

FY20 $0.18FY21 $-0.56FY22 $-0.88FY24 $-1.56

Total Assets

+4.1% YoY

$1.24BFY 2024

FY20 $1.05BFY21 $1.14BFY22 $1.19BFY24 $1.24B

Total Debt

-82.8% YoY

$97.3MFY 2024

FY20 $429.9MFY21 $562.2MFY22 $565.5MFY24 $97.3M

Op. Cash Flow

-185.6% YoY

$-26.4MFY 2024

FY20 $99.1MFY21 $82.8MFY22 $30.8MFY24 $-26.4M

Metric	FY 2024	FY 2022	FY 2021	FY 2020	FY 2017	FY 2016
Revenue	$605.2M +12.5%	$537.8M +0.5%	$535.0M +8.2%	$494.4M +179.3%	$177.0M +113.6%	$82.9M
Net Income	$-168.6M -82.2%	$-92.5M -58.6%	$-58.4M -394.6%	$19.8M +132.1%	$-61.7M +53.2%	$-131.8M
Operating Income	$-170.5M -90.4%	$-89.5M -101.9%	$-44.3M -245.8%	$30.4M +177.3%	$-39.3M +65.9%	$-115.3M
EPS (Diluted)	$-1.56 -77.3%	$-0.88 -57.1%	$-0.56 -411.1%	$0.18	—	—
Total Assets	$1.24B +4.1%	$1.19B +4.6%	$1.14B +8.3%	$1.05B +296.5%	$265.3M -5.9%	$282.1M
Total Debt	$97.3M -82.8%	$565.5M +0.6%	$562.2M +30.8%	$429.9M +341.5%	$97.4M +1.1%	$96.3M
Operating Cash Flow	$-26.4M -185.6%	$30.8M -62.8%	$82.8M -16.5%	$99.1M +399.2%	$-33.1M +69.2%	$-107.6M

AI Insight: NVCR Financial Trends

Revenue reached $174M for the second consecutive quarter in Q1 2026, but net loss widened sharply to $71M — the deepest quarterly loss in the dataset.

• Revenue grew from $150M in Q2 2024 to $174M in Q1 2026, a steady 16% cumulative increase over eight quarters.

• Operating loss widened from $-34M in Q2 2024 to $-67M in Q1 2026, with no quarter yet achieving operating breakeven.

• Equity eroded from $362M in Q2 2024 to $331M in Q1 2026 as accumulated losses outpace any capital inflows.

• Operating cash flow remains highly volatile, swinging from $21M in Q3 2025 to $-18M in Q4 2025 and $-14M in Q1 2026.

⚠ Total debt doubled from $97M in Q4 2024 to $195M in Q4 2025 — rising leverage against a shrinking equity base warrants close monitoring.

⚠ Net loss of $-71M in Q1 2026 diverges sharply from the operating loss of $-67M, suggesting growing below-the-line charges to investigate.

⚠ Revenue has plateaued at $174M for two straight quarters — watch whether Q2 2026 can re-accelerate growth.

AI Insight: NVCR Ratio Trends

NovoCure's profitability deteriorated sharply in Q1 2026, with ROE collapsing to -86.0% and ROIC to -81.5% — the worst readings in the visible dataset.

• Operating margin worsened from -21.5% in Q3 2025 to -38.7% in Q1 2026, erasing sequential improvement seen mid-2025.

• ROA deteriorated from -10.9% in Q3 2025 to -36.1% in Q1 2026, the steepest single-quarter drop in the dataset.

• D/E ratio rose from 0.27 in Q4 2024 to 0.57 in Q4 2025, the only two quarters with available leverage data, signaling rising debt load.

• Q4 2025 offered a brief respite with NPM improving to -14.1% from -22.3% in Q3 2025, but Q1 2026 reversed this entirely.

⚠ ROIC plunged to -81.5% in Q1 2026 from -30.2% in Q4 2025 — worst in the dataset; capital destruction is accelerating.

⚠ D/E data is sparse; the jump from 0.27 to 0.57 warrants close monitoring as losses mount and balance sheet erodes.

⚠ Q1 seasonality has produced sharp margin dips in both 2025 and 2026; confirm whether Q2 2026 recovers toward Q3 2025 levels.

Get alerted when NVCR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NovoCure Ltd including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NVCR

FMR LLC
$186.1M17,069,149 sh
BlackRock, Inc.
$143.8M13,193,765 sh
Soleus Capital Management, L.P.
$114.4M10,492,391 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$68.1M6,251,701 sh
VANGUARD CAPITAL MANAGEMENT LLC
$51.0M4,682,064 sh
MORGAN STANLEY
$49.5M4,541,526 sh
WELLS FARGO & COMPANY/MN
$32.2M2,951,237 sh
STATE STREET CORP
$27.9M2,561,817 sh
GEODE CAPITAL MANAGEMENT, LLC
$27.4M2,511,707 sh
Quantinno Capital Management LP
$27.1M2,487,376 sh

Fund	Value	Shares
FMR LLC	$186.1M	17,069,149
BlackRock, Inc.	$143.8M	13,193,765
Soleus Capital Management, L.P.	$114.4M	10,492,391
VANGUARD PORTFOLIO MANAGEMENT LLC	$68.1M	6,251,701
VANGUARD CAPITAL MANAGEMENT LLC	$51.0M	4,682,064
MORGAN STANLEY	$49.5M	4,541,526
WELLS FARGO & COMPANY/MN	$32.2M	2,951,237
STATE STREET CORP	$27.9M	2,561,817
GEODE CAPITAL MANAGEMENT, LLC	$27.4M	2,511,707
Quantinno Capital Management LP	$27.1M	2,487,376

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NVCR on your watchlist

Track score changes the day NovoCure Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NVCR a good stock to buy?

13F Pro's AI-powered analysis of NovoCure Ltd (NVCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVCR are available on the NVCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NVCR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NovoCure Ltd's investment landscape.